Talk:Low-molecular-weight heparin

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Medicine High‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
High	This article has been rated as High-importance on the project's importance scale.

Early comments edit

Latest comment: 18 years ago2 comments2 people in discussion

Hi, I just have a correction to add.

I believe the statement below is not accurate:

"It is also more selective for thrombin and is a comparatively weak inhibitor of factor Xa"

Long chains of heparin (high molecular weight heparin) have the ability to inactivate thrombin because its long chain allows it to form a complex that 'wraps around' thrombin, thereby inactivating it. It also inactivates factor Xa enzymatically.

Low molecular weight heparin (chains shorter than 16 monomers), on the otherhand, can't complex with thrombin because it is too short, but it still retains the ability to inhbit factor Xa.

The website http://www.uspharmacist.com/oldformat.asp?url=newlook/files/feat/lmwh.htm mentions some of what i'm saying. (search for "factor xa" in that document)

Could you edit the article to this effect? JFW | T@lk 17:29, 8 August 2005 (UTC)Reply

Actually, what I said wasn't entirely correct. (bad memory)

I looked up heparin in my book and was reminded that heparin complexes with antithrombin III (now called antithrombin), not thrombin. Antithrombin complexed with heparin can then inhibit thrombin. Tjsung 00:35, 11 August 2005 (UTC)Reply

References edit

Latest comment: 18 years ago1 comment1 person in discussion

This article needs one or more references to cover the content, added the tag. --FloNight 23:45, 22 November 2005 (UTC)Reply

Improvement in cancer prognosis edit

Latest comment: 17 years ago2 comments1 person in discussion

Fascinating: according to this paper we can improve cancer prognosis with LMWH. When that paper is printed we should cite it. JFW | T@lk 21:10, 6 February 2007 (UTC)Reply

Alternative link - for when the DOI is not yet activated[1]. JFW | T@lk 21:10, 6 February 2007 (UTC)Reply

Some external links edit

Latest comment: 14 years ago1 comment1 person in discussion

I moved the following list of external links to here, since Wikipedia is not a mirror or a repository of links. Please summarize their findings in the article and use them as references instead. Mikael Häggström (talk) 07:53, 24 April 2010 (UTC)Reply

see references.^[1]^[2]^[3]^[4].^[5]^[6]

^ Green, D. Hirsh, J. Heit, J.; et al. (1991). "Low molecular weight heparin: A critical analysis of clinical trials". Pharmacol. Rev. 2: 45–50. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
^ Barrowcliffe, T. W. (1995). "Low molecular weight heparin(s)". Br. J. Haematol. 90 (1): 1–7. doi:10.1111/j.1365-2141.1995.tb03373.x. PMID 7786769.
^ Donayre C. E. (1996). "Current use of low molecular weight heparins". Semin. Vascul. Surg. 9: 362–371.
^ Hunt, D. (1998). "Low molecular weight heparins in clinical practice". Southern Medical J. 91: 2–10.
^ Fareed, J. Jeske, W. Hoppensteadt, D. Clarizio, R. Walenga, J. M. (1998). "Low molecular weight heparins: Pharmacologic profile and product differentiation". Am. J. Cardiol. 82 (5B): 3L–10L. doi:10.1016/S0002-9149(98)00105-2. PMID 9737473.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Ramos-Sánchez MC, Barrio-Arredondo MT, De Andrés Santos AI, Martín-Gil J, Martín-Gil F.J. (1995). "Thermal analysis of aqueous solutions of heparins". Thermochim Acta. 262: 109–115. doi:10.1016/0040-6031(95)02375-C.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Bad placenta edit

Latest comment: 9 years ago1 comment1 person in discussion

doi:10.1111/bjh.13209 LMWH for placenta-related pregnancy complications. JFW | T@lk 10:20, 8 February 2015 (UTC)Reply

Reduced GFR edit

Latest comment: 8 years ago2 comments1 person in discussion

The following was added:

Options for management depend on the degree of renal insufficiency and the available LMW heparin.

For those with a CrCl ≤30 mL/min, use of unfractionated heparin avoids the problems associated with impaired renal clearance of LMW heparin.
If LMW heparin is used in an individual with renal insufficiency, dose-reduction and/or adjustment based on anti-factor Xa levels may be appropriate, especially for enoxaparin.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10] Enoxaparin dose reduction based on anti-factor Xa activity or renal function appears to reduce the risk of bleeding.^[11]^[12] Information in the prescribing information should be consulted for each product, and information from one LMW heparin product should not be extrapolated to a different LMW heparin.

The sourcing is messy with a combination of meta-analyses and primary studies. Ideally this content should be based on clinical guidelines. JFW | T@lk 23:02, 30 December 2015 (UTC)Reply

... such as section 1.2.4 of this: doi:10.1378/chest.11-2291 JFW | T@lk 23:07, 30 December 2015 (UTC)Reply

Making new ones edit

Latest comment: 8 years ago1 comment1 person in discussion

doi:10.1111/jth.13312 JFW | T@lk 23:38, 19 March 2016 (UTC)Reply

External links modified edit

Latest comment: 6 years ago1 comment1 person in discussion

Hello fellow Wikipedians,

I have just modified 2 external links on Low molecular weight heparin. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 18 January 2022).

If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 15:05, 7 January 2018 (UTC)Reply

Add topic

[1] Green, D. Hirsh, J. Heit, J.; et al. (1991). "Low molecular weight heparin: A critical analysis of clinical trials". Pharmacol. Rev. 2: 45–50. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)

[2] Barrowcliffe, T. W. (1995). "Low molecular weight heparin(s)". Br. J. Haematol. 90 (1): 1–7. doi:10.1111/j.1365-2141.1995.tb03373.x. PMID 7786769.

[3] Donayre C. E. (1996). "Current use of low molecular weight heparins". Semin. Vascul. Surg. 9: 362–371.

[4] Hunt, D. (1998). "Low molecular weight heparins in clinical practice". Southern Medical J. 91: 2–10.

[5] Fareed, J. Jeske, W. Hoppensteadt, D. Clarizio, R. Walenga, J. M. (1998). "Low molecular weight heparins: Pharmacologic profile and product differentiation". Am. J. Cardiol. 82 (5B): 3L–10L. doi:10.1016/S0002-9149(98)00105-2. PMID 9737473.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[6] Ramos-Sánchez MC, Barrio-Arredondo MT, De Andrés Santos AI, Martín-Gil J, Martín-Gil F.J. (1995). "Thermal analysis of aqueous solutions of heparins". Thermochim Acta. 262: 109–115. doi:10.1016/0040-6031(95)02375-C.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[7] ttp://www.ncbi.nlm.nih.gov/pubmed?term=22315264

[8] ttp://www.ncbi.nlm.nih.gov/pubmed?term=12456233

[9] ttp://www.ncbi.nlm.nih.gov/pubmed?term=17393021

[10] ttp://www.ncbi.nlm.nih.gov/pubmed?term=11127859

[11] ttp://www.ncbi.nlm.nih.gov/pubmed?term=21819539

[12] ttp://www.ncbi.nlm.nih.gov/pubmed?term=12817521

[13] ttp://www.ncbi.nlm.nih.gov/pubmed?term=19624460

[14] ttp://www.ncbi.nlm.nih.gov/pubmed?term=18779469

[15] ttp://www.ncbi.nlm.nih.gov/pubmed?term=19175499

[16] ttp://www.ncbi.nlm.nih.gov/pubmed?term=21505722

[17] ttp://www.ncbi.nlm.nih.gov/pubmed?term=16670137

[18] ttp://www.ncbi.nlm.nih.gov/pubmed?term=17940486

[1]

[2]

[3]

[4]

[5]

[6]

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]